Cover Image
市場調查報告書

治療疫苗的全球市場:產業預測,競爭分析,預測

Therapeutic Vaccines Market by Products and by Technology : Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022

出版商 Zion Market Research 商品編碼 580789
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
治療疫苗的全球市場:產業預測,競爭分析,預測 Therapeutic Vaccines Market by Products and by Technology : Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022
出版日期: 2017年03月02日 內容資訊: 英文 110 Pages
簡介

本報告提供治療疫苗的全球市場調查,市場、產業概要,各產品、技術、地區的市場趨勢,收益額的變化與預測,市場促進、阻礙因素及市場機會、課題分析,市場未來展望,競爭情形,主要企業的簡介等系統性資訊。

第1章 簡介

  • 報告概要
  • 調查範圍
  • 調查手法

第2章 摘要整理

  • 市場規模的變化與預測
  • 市場概要

第3章 市場動態

  • 簡介
  • 市場的推動要素
  • 市場阻礙因素
  • 市場機會
  • 波特的五力分析

第4章 競爭情形

  • 企業的市場佔有率
  • 策略趨勢
    • 合併、收購
    • 新產品的上市
    • 協定、合作、聯盟、合資企業
    • 研究開發、種類、事業擴張
  • 產品系列

第5章 治療疫苗的全球市場:各產品

  • 各產品的市場概要
  • 中毒疫苗
  • 自體免疫疾病疫苗
  • 感染疾病疫苗
  • 神經疾病疫苗

第6章 治療疫苗的全球市場:各技術

  • 各技術的市場概要
  • 自體疫苗
  • 同類疫苗

第7章 治療疫苗的全球市場:各地區

  • 各地區的市場概要
  • 北美
    • 美國
  • 歐洲
    • 德國
    • 法國
    • 英國
  • 亞太地區
    • 中國
    • 日本
    • 日本
  • 南美
    • 巴西
  • 中東、非洲

第8章 企業簡介

  • Valeant Pharmaceuticals
  • Agenus Inc.
  • GlaxoSmithKline plc.
  • Immunocellular Therapeutics, Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Argos Therapeutics
  • Bavarian Nordic
  • Galena Biopharma
  • Transgene
  • Vaccinogen, Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The report covers forecast and analysis for the therapeutic vaccines market on a global and regional level. The study provides historic data from 2014 along with a forecast for 2017 to 2022 based revenue (USD Billion). The study includes drivers and restraints for the therapeutic vaccines market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the therapeutic vaccines market on a global level.

In order to give the users of this report a comprehensive view on the therapeutic vaccines market, we have to include competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein product segments and technology segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new therapy launch, agreements, partnerships, collaborations joint ventures, research development, therapy and regional expansion of major participants involved in the market on the global and regional basis.

The study provides a decisive view on the therapeutic vaccines market by segmenting the market based on therapy, technology, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2022. Based on the product the market is segmented into addiction vaccines, autoimmune disease vaccines, infectious disease vaccines and neurological disease vaccines. The technology segment is classified into autologous vaccines and allogeneic vaccines. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America and the Middle East Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for therapeutic vaccines based on the individual segment in all the regions and countries.

Some of the key players in therapeutic vaccines market include Valeant Pharmaceuticals, BioVex, Inc., Inovio Pharmaceuticals, Inc., Immunocellular Therapeutics, Ltd., Agenus Inc., GlaxoSmithKline plc., Pfizer Inc., Novartis AG, Argos Therapeutics, Bavarian Nordic, Transgene, Galena Biopharma and Vaccinogen, Inc. among others.

This report segments the global therapeutic vaccines market as follows:

Global Therapeutic Vaccines Market: Product Segment Analysis

  • Addiction Vaccines
  • Autoimmune Disease Vaccines
  • Infectious Disease Vaccines
  • Neurological Disease Vaccines

Global Therapeutic Vaccines Market: Technology Segment Analysis

  • Autologous vaccines
  • Allogeneic vaccines

Global Therapeutic Vaccines Market: Regional Segment Analysis

  • North America
  • U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa

Table of Contents

Chapter 1. Introduction

  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology

Chapter 2. Executive Summary

  • 2.1. Global therapeutic vaccines market, 2016 2022 (USD Billion)
  • 2.2. Global therapeutic vaccines market : Snapshot

Chapter 3. Therapeutic Vaccines Market Dynamics

  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global therapeutic vaccines market drivers: Impact analysis
    • 3.2.2. Growing incidences of chronic diseases
    • 3.2.3. Technological advancements
  • 3.3. Market restraints
    • 3.3.1. Global therapeutic vaccines market restraints: Impact analysis
    • 3.3.2. High treatment cost
  • 3.4. Opportunities
    • 3.4.1. Increasing focus on personalized medicine
  • 3.5. Porters five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. Threat from new entrants
    • 3.5.4. Threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by product segment
    • 3.6.2. Market attractiveness analysis, by technology segment
    • 3.6.3. Market attractiveness analysis, by regional segment

Chapter 4. Global Therapeutic Vaccines Market Competitive Landscape

  • 4.1. Company Market Share Analysis
    • 4.1.1. Global therapeutic vaccines market: company market share, 2015
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions Mergers
    • 4.2.2. New Therapy Launch
    • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
    • 4.2.4. Research and Development, Therapy and Regional Expansion

Chapter 5. Global Therapeutic Vaccines Market Product Segment Analysis

  • 5.1. Global therapeutic vaccines market: Product overview
    • 5.1.1. Global therapeutic vaccines market revenue share, by product, 2014 and 2022
  • 5.2. Addiction Vaccines
    • 5.2.1. Global addiction vaccines market , 2014 2022(USD Billion)
  • 5.3. Autoimmune Disease Vaccines
    • 5.3.1. Global autoimmune disease vaccines market , 2014 2022(USD Billion)
  • 5.4. Infectious Disease Vaccines
    • 5.4.1. Global infectious disease vaccines market , 2014 2022(USD Billion)
  • 5.5. Neurological Disease Vaccines
    • 5.5.1. Global neurological disease vaccines market , 2014 2022(USD Billion)

Chapter 6. Global Therapeutic vaccines Market Technology Segment Analysis

  • 6.1. Global therapeutic vaccines market: Technology overview
    • 6.1.1. Global therapeutic vaccines market revenue share, by technology, 2016 and 2022
  • 6.2. Autologous vaccines
    • 6.2.1. Global therapeutic vaccines market for autologous vaccines, 2014 2022 (USD Billion)
  • 6.3. Allogeneic Vaccines
    • 6.3.1. Global therapeutic vaccines market for allogeneic vaccines, 2014 2022(USD Billion)

Chapter 7. Global Therapeutic vaccines Market Regional Segment Analysis

  • 7.1. Global therapeutic vaccines market: Regional overview
    • 7.1.1. Global therapeutic vaccines market revenue share, by region, 2016 and 2022
  • 7.2. North America
    • 7.2.1. North America therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
    • 7.2.2. North America therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
    • 7.2.3. U.S.
      • 7.2.3.1. U.S. therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
      • 7.2.3.2. U.S. therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
    • 7.3.2. Europe therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
      • 7.3.3.2. Germany therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
      • 7.3.4.2. France therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
    • 7.3.5. UK
      • 7.3.5.1. UK therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
      • 7.3.5.2. UK therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific therapeutic vaccines market revenue, by product, 2014 2022, (USD Billion)
    • 7.4.2. Asia Pacific therapeutic vaccines market revenue, by technology, 2014 2022, (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
      • 7.4.3.2. China therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
    • 7.4.4. Japan
      • 7.4.4.1. Japan therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
      • 7.4.4.2. Japan therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
    • 7.4.5. India
      • 7.4.5.1. India therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
      • 7.4.5.2. India therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
    • 7.5.2. Latin America therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)
    • 7.5.3. Brazil
      • 7.5.3.1. Brazil therapeutic vaccines market revenue, by product, 2014 2022(USD Billion)
      • 7.5.3.2. Brazil therapeutic vaccines market revenue, by technology, 2014 2022 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa therapeutic vaccines market revenue, by product, 2014 2022 (USD Billion)
    • 7.6.2. Middle East and Africa therapeutic vaccines market revenue, by technology, 2014 2022(USD Billion)

Chapter 8. Company Profile

  • 8.1. Valeant Pharmaceuticals
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Therapy portfolio
    • 8.1.4. Business strategy
    • 8.1.5. Recent developments
  • 8.2. Agenus Inc.
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Therapy portfolio
    • 8.2.4. Business strategy
    • 8.2.5. Recent developments
  • 8.3. GlaxoSmithKline plc.
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Therapy portfolio
    • 8.3.4. Business strategy
    • 8.3.5. Recent developments
  • 8.4. Immunocellular Therapeutics, Ltd.
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Therapy portfolio
    • 8.4.4. Business strategy
    • 8.4.5. Recent developments
  • 8.5. Pfizer Inc.
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Therapy portfolio
    • 8.5.4. Business strategy
    • 8.5.5. Recent developments
  • 8.6. Novartis AG
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Therapy portfolio
    • 8.6.4. Business strategy
    • 8.6.5. Recent developments
  • 8.7. Argos Therapeutics
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Therapy portfolio
    • 8.7.4. Business strategy
    • 8.7.5. Recent developments
  • 8.8. Bavarian Nordic
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Therapy portfolio
    • 8.8.4. Business strategy
    • 8.8.5. Recent developments
  • 8.9. Galena Biopharma
    • 8.9.1. Overview
    • 8.9.2. Financials
    • 8.9.3. Therapy portfolio
    • 8.9.4. Business strategy
    • 8.9.5. Recent developments
  • 8.10. Transgene
    • 8.10.1. Overview
    • 8.10.2. Financials
    • 8.10.3. Therapy portfolio
    • 8.10.4. Business strategy
    • 8.10.5. Recent developments
  • 8.11. Vaccinogen, Inc.
    • 8.11.1. Overview
    • 8.11.2. Financials
    • 8.11.3. Therapy portfolio
    • 8.11.4. Business strategy
    • 8.11.5. Recent developments
Back to Top